<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128635</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000438768</org_study_id>
    <secondary_id>NABTT-0404</secondary_id>
    <nct_id>NCT00128635</nct_id>
  </id_info>
  <brief_title>Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>An Open-Label, Dose Confirmation and Dosimetry Study of Interstitial 131 I-chTNT-1/B MAb (COTARA(TM)) For the Treatment of Glioblastoma Multiforme (GBM) at 1st or 2nd Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody&#xD;
      TNT-1/B (^131I MOAB TNT-1/B), can find tumor cells and carry tumor-killing substances to them&#xD;
      without harming normal cells. This may be an effective treatment for glioblastoma multiforme.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of ^131I MOAB TNT-1/B&#xD;
      in treating patients with progressive or recurrent glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of iodine I 131 monoclonal antibody TNT-1/B in&#xD;
           patients with progressive or recurrent glioblastoma multiforme.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the biodistribution and radiation dosimetry of this drug in these patients.&#xD;
&#xD;
        -  Determine the toxicity and tolerability of this drug in these patients.&#xD;
&#xD;
        -  Determine the overall survival, median time of survival, and 6-month survival of&#xD;
           patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter, dose-escalation study of therapeutic doses of&#xD;
      iodine I 131 monoclonal antibody TNT-1/B (^131I MOAB TNT-1/B).&#xD;
&#xD;
      The first 12 patients accrued to the study undergo stereotactic placement of 2 catheters&#xD;
      within the contrast-enhancing tumor on day 0. These patients then receive an imaging dose of&#xD;
      ^131I MOAB TNT-1/B interstitially over approximately 25 hours on day 1 followed by dosimetry,&#xD;
      biodistribution evaluations, and whole body imaging over an 8-10 day period. Beginning at&#xD;
      least 2 weeks, but no more than 4 weeks later, all patients undergo catheter placement as&#xD;
      above. One day later, patients receive a therapeutic dose of ^131I MOAB TNT-1/B&#xD;
      interstitially over approximately 25 hours.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating therapeutic doses of ^131I MOAB TNT-1/B until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 10 patients&#xD;
      are treated at the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed weekly for 3 weeks, at 6 weeks, at&#xD;
      4, 8, and 12 weeks (for the first 12 patients accrued to the study), every 4 weeks until&#xD;
      disease progression, and then every 8 weeks thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 22 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose based on CTCAE v3.0 weekly for 8 weeks then every 8 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biodistribution and radiation dosimetry by blood, urine, and whole body scans daily for 10 days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity by CTCAE v3.0 weekly for 12 weeks then every 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival, median time of survival, and percent alive at 6 months</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody TNT-1/B</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed glioblastoma multiforme&#xD;
&#xD;
               -  Focal disease&#xD;
&#xD;
               -  Progressive or recurrent disease after prior treatment with radiotherapy and/or&#xD;
                  chemotherapy&#xD;
&#xD;
               -  Low-grade astrocytoma that progressed to glioblastoma multiforme after prior&#xD;
                  radiotherapy and/or chemotherapy allowed&#xD;
&#xD;
          -  Gross tumor volume 5-60 mL&#xD;
&#xD;
          -  No intraventricular tumor, infratentorial tumor, or tumor that communicates with the&#xD;
             ventricles&#xD;
&#xD;
          -  No bilateral non-contiguous gadolinium-enhancing tumor&#xD;
&#xD;
          -  No diffuse disease, defined as any satellite lesion &gt; 1.5 cm from the anticipated&#xD;
             location of a catheter tip OR &gt; 2 satellite lesions&#xD;
&#xD;
          -  No ventricular invasion outside the anticipated radiotherapy volume&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Hepatitis B negative&#xD;
&#xD;
          -  No evidence of active hepatitis&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.7 mg/dL&#xD;
&#xD;
          -  BUN ≤ 2 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No uncontrolled cardiac dysrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to undergo MRI&#xD;
&#xD;
          -  Mini Mental State Exam score ≥ 15&#xD;
&#xD;
          -  No serious infection&#xD;
&#xD;
          -  No other medical illness that would preclude study participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated carcinoma in&#xD;
             situ or basal cell skin cancer&#xD;
&#xD;
          -  No psychological or sociological condition, addictive disorder, or other condition&#xD;
             that would preclude study compliance&#xD;
&#xD;
          -  No known or suspected allergy to study drug or iodine&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior monoclonal antibodies&#xD;
&#xD;
          -  No prior local immunotherapy or treatment with the following biologic agents:&#xD;
&#xD;
               -  Immunotoxins&#xD;
&#xD;
               -  Immunoconjugates&#xD;
&#xD;
               -  Antiangiogenesis compounds&#xD;
&#xD;
               -  Antisense agents&#xD;
&#xD;
               -  Peptide receptor antagonist&#xD;
&#xD;
               -  Interferons&#xD;
&#xD;
               -  Interleukins&#xD;
&#xD;
               -  Tumor infiltrating lymphocytes&#xD;
&#xD;
               -  Lymphokine-activated killer cells&#xD;
&#xD;
               -  Gene therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  At least 3 months since prior polifeprosan 20 with carmustine implant (Gliadel wafer^®&#xD;
             )&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Must be maintained on a stable corticosteroid dose (approximately 4 mg) for ≥ 2 weeks&#xD;
             before study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 months since prior radiotherapy&#xD;
&#xD;
          -  No prior brachytherapy or radiosurgery&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 1 month since prior investigational agents&#xD;
&#xD;
          -  No more than 2 prior treatment regimens&#xD;
&#xD;
          -  No other prior local therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A. Lustig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Judy, MD</last_name>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

